Madrigal’s Rezdiffra Continues Its Solid Launch

 
• By Joseph Haas

With $180m in sales during its first nine months on the US market, the first approved MASH drug still tops projections. Madrigal predicts continued growth in 2025, with EU entry expected.

Set of Three Increasing Size Red and White Cartoon Spaceships on Dark Background
Madrigal's Rezdiffra continued its early growth through three quarters on the market • Source: Alamy

Madrigal’s successful launch of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom) continued during the fourth quarter and on 26 February the company predicted strong year-over-year sales growth for 2025, driven partially by expected EU approval and initial launch in Germany later this year.

Key Takeaways
  • Madrigal continues to beat Wall Street projections for the launch of Rezdiffra, the first approved MASH drug.

The Conshohocken, PA-based company also reported two-year data from a cohort of MASH patients with cirrhosis from an ongoing study,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?